Cabozantinib
- TRADE NAMES: Carbometyx (Exelixis); Cometriq (Exelixis)
- INDICATIONS: Metastatic medullary thyroid cancer (Cometriq); advanced renal cell carcinoma (Cabometyx)
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 55 hours (Cometriq); 99 hours (Cabometyx)
FDA APPROVAL DATE: 11/30/2012 (Cometriq); 04/25/2016 (Cabometyx)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Atazanavir, Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Voriconazole
PREGNANCY CATEGORY: D
PERFORATIONS AND FISTULAS, and HEMORRHAGE
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 03/09/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric